Which has stronger earnings & valuation, XERS or MANE?

Xeris Biopharma has higher revenue and earnings than Veradermics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xeris Biopharma $291.85M 3.48 $550K $0.06 98.17 Veradermics N/A N/A N/A N/A N/A

Does the media refer more to XERS or MANE?

In the previous week, Veradermics had 4 more articles in the media than Xeris Biopharma. MarketBeat recorded 8 mentions for Veradermics and 4 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.85 beat Veradermics' score of 0.34 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to XERS or NAMS?

In the previous week, NewAmsterdam Pharma had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for NewAmsterdam Pharma and 4 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.85 beat NewAmsterdam Pharma's score of 0.76 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XERS or TVTX?

In the previous week, Travere Therapeutics had 5 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Travere Therapeutics and 4 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.85 beat Travere Therapeutics' score of 0.59 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AMRX or XERS?

In the previous week, Xeris Biopharma had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 4 mentions for Xeris Biopharma and 2 mentions for Amneal Pharmaceuticals. Xeris Biopharma's average media sentiment score of 0.85 beat Amneal Pharmaceuticals' score of 0.72 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xeris Biopharma (XERS) Competitors

$5.89 -0.11 (-1.83%)

Closing price 04:00 PM Eastern

Extended Trading

$5.90 +0.01 (+0.19%)

As of 07:58 PM Eastern

Compare

XERS vs. MANE, NAMS, TVTX, KNSA, and AMRX

Should you buy Xeris Biopharma stock or one of its competitors? MarketBeat compares Xeris Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xeris Biopharma include MANE (MANE), NewAmsterdam Pharma (NAMS), Travere Therapeutics (TVTX), Kiniksa Pharmaceuticals International (KNSA), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

How does Xeris Biopharma compare to Veradermics?

Xeris Biopharma (NASDAQ:XERS) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Xeris Biopharma presently has a consensus price target of $10.80, suggesting a potential upside of 83.36%. Veradermics has a consensus price target of $109.00, suggesting a potential upside of 12.37%. Given Xeris Biopharma's higher probable upside, equities analysts clearly believe Xeris Biopharma is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

42.8% of Xeris Biopharma shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Xeris Biopharma has a net margin of 3.81% compared to Veradermics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Veradermics	N/A	N/A	N/A

In the previous week, Veradermics had 4 more articles in the media than Xeris Biopharma. MarketBeat recorded 8 mentions for Veradermics and 4 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.85 beat Veradermics' score of 0.34 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xeris Biopharma has higher revenue and earnings than Veradermics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.48	$550K	$0.06	98.17
Veradermics	N/A	N/A	N/A	N/A	N/A

Summary

Xeris Biopharma beats Veradermics on 8 of the 11 factors compared between the two stocks.

How does Xeris Biopharma compare to NewAmsterdam Pharma?

Xeris Biopharma (NASDAQ:XERS) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, NewAmsterdam Pharma had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for NewAmsterdam Pharma and 4 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.85 beat NewAmsterdam Pharma's score of 0.76 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has a net margin of 3.81% compared to NewAmsterdam Pharma's net margin of -943.23%. Xeris Biopharma's return on equity of 735.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Xeris Biopharma has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.48	$550K	$0.06	98.17
NewAmsterdam Pharma	$22.57M	166.35	-$203.82M	-$1.79	N/A

Xeris Biopharma has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

Xeris Biopharma currently has a consensus target price of $10.80, indicating a potential upside of 83.36%. NewAmsterdam Pharma has a consensus target price of $48.00, indicating a potential upside of 49.49%. Given Xeris Biopharma's higher possible upside, equities analysts clearly believe Xeris Biopharma is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Xeris Biopharma beats NewAmsterdam Pharma on 10 of the 17 factors compared between the two stocks.

How does Xeris Biopharma compare to Travere Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, Travere Therapeutics had 5 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Travere Therapeutics and 4 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.85 beat Travere Therapeutics' score of 0.59 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Xeris Biopharma has a net margin of 3.81% compared to Travere Therapeutics' net margin of -4.00%. Xeris Biopharma's return on equity of 735.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Xeris Biopharma currently has a consensus target price of $10.80, indicating a potential upside of 83.36%. Travere Therapeutics has a consensus target price of $48.92, indicating a potential upside of 8.22%. Given Xeris Biopharma's higher possible upside, equities analysts clearly believe Xeris Biopharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Xeris Biopharma has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.48	$550K	$0.06	98.17
Travere Therapeutics	$490.73M	8.57	-$25.55M	-$0.23	N/A

42.8% of Xeris Biopharma shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Xeris Biopharma beats Travere Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Kiniksa Pharmaceuticals International?

Xeris Biopharma (NASDAQ:XERS) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Xeris Biopharma has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Xeris Biopharma. Kiniksa Pharmaceuticals International is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.48	$550K	$0.06	98.17
Kiniksa Pharmaceuticals International	$677.56M	5.43	$59.01M	$0.90	53.17

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Xeris Biopharma had 1 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 4 mentions for Xeris Biopharma and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.99 beat Xeris Biopharma's score of 0.85 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Xeris Biopharma's net margin of 3.81%. Xeris Biopharma's return on equity of 735.00% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Xeris Biopharma currently has a consensus price target of $10.80, indicating a potential upside of 83.36%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, indicating a potential upside of 27.18%. Given Xeris Biopharma's higher possible upside, analysts plainly believe Xeris Biopharma is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Kiniksa Pharmaceuticals International beats Xeris Biopharma on 11 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Amneal Pharmaceuticals has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

In the previous week, Xeris Biopharma had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 4 mentions for Xeris Biopharma and 2 mentions for Amneal Pharmaceuticals. Xeris Biopharma's average media sentiment score of 0.85 beat Amneal Pharmaceuticals' score of 0.72 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a net margin of 4.01% compared to Xeris Biopharma's net margin of 3.81%. Xeris Biopharma's return on equity of 735.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Xeris Biopharma	3.81%	735.00%	3.24%

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has higher revenue and earnings than Xeris Biopharma. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.36	$72.06M	$0.38	33.89
Xeris Biopharma	$291.85M	3.48	$550K	$0.06	98.17

Amneal Pharmaceuticals currently has a consensus price target of $15.17, suggesting a potential upside of 17.75%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 83.36%. Given Xeris Biopharma's higher possible upside, analysts clearly believe Xeris Biopharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Amneal Pharmaceuticals beats Xeris Biopharma on 9 of the 16 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XERS vs. The Competition

Export

Metric	Xeris Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.02B	$2.91B	$6.45B	$12.42B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	98.17	17.69	22.30	24.19
Price / Sales	3.48	739.65	581.44	138.36
Price / Cash	60.60	56.38	42.31	57.88
Price / Book	73.63	3.85	9.84	6.72
Net Income	$550K	$75.85M	$3.57B	$337.19M
7 Day Performance	-5.46%	-1.67%	-1.16%	0.48%
1 Month Performance	-6.21%	22.18%	3.85%	5.07%
1 Year Performance	26.67%	21.83%	27.40%	34.25%

Xeris Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XERS Xeris Biopharma	3.5708 of 5 stars	$5.89 -1.8%	$10.80 +83.4%	+18.8%	$1.04B	$291.85M	98.17	290	Insider Trade
MANE MANE	N/A	$101.42 -0.2%	$100.00 -1.4%	N/A	$4.24B	N/A	N/A	19	Analyst Forecast Gap Up
NAMS NewAmsterdam Pharma	3.4538 of 5 stars	$35.44 flat	$48.00 +35.4%	+67.5%	$4.14B	$22.50M	N/A	4	Positive News
TVTX Travere Therapeutics	2.0161 of 5 stars	$44.43 flat	$47.83 +7.7%	+176.7%	$4.13B	$490.73M	N/A	460	News Coverage Analyst Forecast
KNSA Kiniksa Pharmaceuticals International	4.3866 of 5 stars	$53.24 flat	$60.86 +14.3%	+68.1%	$4.10B	$677.56M	59.16	220

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XERS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Competitors

XERS vs. MANE, NAMS, TVTX, KNSA, and AMRX

How does Xeris Biopharma compare to Veradermics?

Summary

How does Xeris Biopharma compare to NewAmsterdam Pharma?

Summary

How does Xeris Biopharma compare to Travere Therapeutics?

Summary

How does Xeris Biopharma compare to Kiniksa Pharmaceuticals International?

Summary

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Competitors

XERS vs. MANE, NAMS, TVTX, KNSA, and AMRX

How does Xeris Biopharma compare to Veradermics?

Do analysts rate XERS or MANE?

Do institutionals and insiders hold more shares of XERS or MANE?

Is XERS or MANE more profitable?

Does the media refer more to XERS or MANE?

Which has stronger earnings & valuation, XERS or MANE?

Summary

How does Xeris Biopharma compare to NewAmsterdam Pharma?

Does the media refer more to XERS or NAMS?

Is XERS or NAMS more profitable?

Which has preferable valuation and earnings, XERS or NAMS?

Which has more volatility and risk, XERS or NAMS?

Do analysts recommend XERS or NAMS?

Do institutionals & insiders believe in XERS or NAMS?

Summary

How does Xeris Biopharma compare to Travere Therapeutics?

Does the media favor XERS or TVTX?

Which has more risk and volatility, XERS or TVTX?

Is XERS or TVTX more profitable?

Do analysts rate XERS or TVTX?

Which has stronger earnings and valuation, XERS or TVTX?

Do insiders & institutionals hold more shares of XERS or TVTX?

Summary

How does Xeris Biopharma compare to Kiniksa Pharmaceuticals International?

Which has more risk and volatility, XERS or KNSA?

Which has preferable earnings and valuation, XERS or KNSA?

Do institutionals and insiders believe in XERS or KNSA?

Does the media refer more to XERS or KNSA?

Is XERS or KNSA more profitable?

Do analysts rate XERS or KNSA?

Summary

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Which has more volatility & risk, AMRX or XERS?

Does the media refer more to AMRX or XERS?

Is AMRX or XERS more profitable?

Do institutionals and insiders have more ownership in AMRX or XERS?

Which has higher valuation and earnings, AMRX or XERS?

Do analysts prefer AMRX or XERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools